Literature DB >> 17460520

Gamma knife surgery for facial nerve schwannomas.

Claude F Litre, Grégoire P Gourg, Manabu Tamura, Driss Mdarhri, Adil Touzani, Pierre H Roche, Jean Régis.   

Abstract

OBJECTIVE: Radical resection of facial nerve schwannomas classically implies a high risk of severe facial palsy. Owing to the rarity of facial palsy after gamma knife surgery (GKS) of vestibular schwannomas, functional evaluation after GKS seems rational in this specific group of patients. To our knowledge, no previous similar evaluation exists in the literature.
METHODS: Of 1783 schwannomas of the cerebellopontine angles treated by GKS at Timone University Hospital between July 1992 and May 2003, 11 were diagnosed as originating from the facial nerve. Criteria for this diagnosis were the involvement of the tympanic or mastoid segment of the facial nerve (n = 9) and/or preoperative observation of a facial nerve deficit that had occurred during previous microsurgery (two patients). The rare occurrence of facial palsy after vestibular schwannoma radiosurgery, usually within 18 months of treatment, has been considered only in the patients with more than 2 years of follow-up (n = 9).
RESULTS: Six of these patients experienced a previous spontaneous facial palsy on one (n = 4) or several occasions (n = 2). A normal motor facial function was observed in only three patients before GKS (House-Brackmann Grade II in six patients, Grade III in one patient, Grade IV in one patient). The median follow-up period was 39 months (range, 18-84 mo). At the time of the last follow-up examination, no patients had developed a new facial palsy or experienced deterioration of a preexisting facial palsy and three patients had improvement of a preoperative facial palsy. Ten out of the 11 tumors are stable or decreased in size; in the other, a microsurgical resection of the tumor had been recommended owing to the development of a cyst. Clinical management owing to the specificity and heterogeneity of this group of patients has required the development of an original classification of four anatomic subtypes presenting different clinical and surgical difficulties.
CONCLUSION: This first study demonstrates that radiosurgery allows treatment of these patients while preserving normal motor facial function. Such an advantage should lead to the consideration of GKS as a first treatment option for small- to medium-size facial nerve schwannomas.

Entities:  

Mesh:

Year:  2007        PMID: 17460520     DOI: 10.1227/01.NEU.0000249282.46514.DA

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Facial nerve schwannomas of the cerebellopontine angle: the mayo clinic experience.

Authors:  Jeffrey T Jacob; Colin L W Driscoll; Michael J Link
Journal:  J Neurol Surg B Skull Base       Date:  2012-08

2.  Facial Schwannomas: Various Presentations and their Management with Literature Review.

Authors:  Ashish Kumar; Chandrashekhar Deopujari; Anand Shah
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-20

3.  Fractionated Stereotactic Radiotherapy for Facial Nerve Schwannomas.

Authors:  Wenyin Shi; Varsha Jain; Hyun Kim; Colin Champ; Gaurav Jain; Christopher Farrell; David W Andrews; Kevin Judy; Haisong Liu; Gregory Artz; Maria Werner-Wasik; James J Evans
Journal:  J Neurol Surg B Skull Base       Date:  2015-09-14

Review 4.  Intratemporal facial nerve schwannoma: clinical presentation and management.

Authors:  Ghizlene Lahlou; Yann Nguyen; Francesca Yoshie Russo; Evelyne Ferrary; Olivier Sterkers; Daniele Bernardeschi
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-16       Impact factor: 2.503

5.  Facial nerve schwannoma: A case report and review of the literature.

Authors:  Mei-Chien Chen; Te-Ming Tseng; Shih-Han Hung; Po-Yueh Chen
Journal:  Oncol Lett       Date:  2014-09-18       Impact factor: 2.967

6.  A meta-analysis of treatment of vestibular schwannoma using Gamma Knife radiosurgery.

Authors:  Bartosz Rykaczewski; Miroslaw Zabek
Journal:  Contemp Oncol (Pozn)       Date:  2014-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.